Drug Trial Radar · NCT05709171
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 17, 2023
Primary completion
Jan 1, 2025
Study completion Jan 1, 2026
Sponsor
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective clinical trial investigating combined, dual 18F-FDG PET/CT and 64Cu-DOTATATE PET/CT imaging of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)
Conditions
- GEP-NET
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Neuroendocrine Carcinoma Metastatic
Interventions
18F-FDGDrug
PET/CT scan approximately 60 min after injection of 18F-FDG
64Cu-DotatateDrug
PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: 12 months after last-patients-last-visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.